Business
Tonix Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights
Data from Animal Studies of COVID-19 Vaccine Candidate, TNX-1800, Expected in Fourth Quarter 2020 Phase 1 Safety Study in Humans of TNX-1800 Expected to be
About this update from Tonix Pharmaceuticals Holding Corp.
[{"type":"text","content":"Data from Animal Studies of COVID-19 Vaccine Candidate, TNX-1800, Expected in Fourth Quarter 2020\n Phase 1 Safety Study in Humans of TNX-1800 Expected to be Initiated in 2021 CHATHAM, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2020, and provided an overview of recent operational highlights. “This is an exciting time for Tonix as we advance TNX-1800, our COVID-19 vaccine candidate, and expect to report our first data from animal studies before year end,” said Seth Lederman, M.D., President and Chief Executive Officer. “In 2021, we anticipate initiation of a Phase 1 study in humans. TNX-1800 is a live replicating vaccine based on our proprietary horsepox vector system and is designed to elicit a strong and durable T cell response in addition to antibody response to SARS-CoV-2 (CoV-2), the virus that causes COVID-19.” Recent Highlights Research and Development TNX-1800 (live attenuated vaccine based on Tonix’s horsepox virus vector): COVID-19 vaccine candidate designed as a single-administration vaccine to elicit T cell immunity Data from small animal and non-human primate studies of TNX-1800 in COVID-19 models to measure safety and the immune response to the CoV-2 Spike protein are expected in the fourth quarter of 2020.Data from small animal and non-human primate studies of TNX-1800 to measure efficacy in CoV-2 challenge studies are expected in the first quarter of 2021. COV-LOGIC, observational study: COVID-19 research collaboration with Southern Research In September, Tonix announced that the first healthy volunteer was enrolled in the observational COV-LOGIC study, a multi-cohort sample collection study of T cell and antibody immune responses to CoV-2 in volunteers who have recovered or remain asymptomatic after exposure to COVID-19. The research is part of an ongoing and broader collaboration between Tonix and Southern Research to develop and conduct animal testing of Tonix’s COVID-19 vaccine candidate TNX-1800.Data are expected in the first half of 2021. PRECISION, observational study: COVID-19 research collaboration with Columbia University In October, Tonix announced enrollment of the first participant in the observational PRECISION ...